Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
157M
-
Number of holders
-
236
-
Total 13F shares, excl. options
-
89.4M
-
Shares change
-
-355K
-
Total reported value, excl. options
-
$1.36B
-
Value change
-
-$24.6M
-
Put/Call ratio
-
0.66
-
Number of buys
-
115
-
Number of sells
-
-104
-
Price
-
$15.21
Significant Holders of TG THERAPEUTICS, INC. - Common Stock (TGTX) as of Q1 2024
299 filings reported holding TGTX - TG THERAPEUTICS, INC. - Common Stock as of Q1 2024.
TG THERAPEUTICS, INC. - Common Stock (TGTX) has 236 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 89.4M shares
of 157M outstanding shares and own 56.83% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (13.5M shares), BlackRock Inc. (10.8M shares), STATE STREET CORP (7.8M shares), MILLENNIUM MANAGEMENT LLC (3.48M shares), PICTET ASSET MANAGEMENT Holding SA (3.33M shares), Soleus Capital Management, L.P. (3.17M shares), WELLINGTON MANAGEMENT GROUP LLP (3.15M shares), GEODE CAPITAL MANAGEMENT, LLC (3.11M shares), Opaleye Management Inc. (2.28M shares), and BANK OF AMERICA CORP /DE/ (2.2M shares).
This table shows the top 236 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.